Vernalis appoints new CEO and CFO
This article was originally published in Scrip
Vernalishas appointed Ian Garland chief executive officer, effective December, and David Mackney chief financial officer, effective February 2009. From May 2007 until September 2008, Mr Garland was CEO of Acambis. He has also served as CFO of Arrow Therapeutics, and as president and chief operating officer of Celltech Pharmaceuticals. From February 2008 to date, Mr Mackney has served as interim CFO at Acambis, working with Mr Garland to secure the US biodefence contract and the secondary financing. Before this he was CFO for a private equity-backed technology company.
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.